-
帕金森病(PD)仅次于阿尔茨海默病,在中老年的神经系统变性疾病中高居第二位,其患病人数在未来将持续增长并长期维持在高水平状态[1]。临床表现分为运动症状和非运动症状,其中认知功能障碍是常见的非运动症状,也是PD前期重要的生物标记物和表现形式,严重影响病人的日常生活质量。研究[2-3]表明,我国汉族人群中PD病人伴有轻度认知功能障碍者约29.1%,且约30%的PD病人会随着疾病的进展而出现PD痴呆,建议对诊断PD病人行常规认知筛查,对于高风险病人进行早期识别和治疗干预。PD的主要病理改变为多巴胺能神经元变性、缺失,黑质-纹状体通路病变及胞质内路易小体的形成。近年来对PD病人行认知功能早期筛查及诊治的相关研究已成为研究热点,本研究旨在探讨血清半胱氨酸蛋白酶抑制剂C(胱抑素C)、血尿酸水平与PD伴认知功能障碍的相关性。
-
PD组血清胱抑素C水平高于对照组(P < 0.05),血尿酸水平明显低于对照组(P < 0.01)(见表 1)。PD伴认知功能障碍组血清胱抑素C水平明显高于不伴认知功能障碍组(P < 0.01),血尿酸水平低于不伴认知功能障碍组(P < 0.05)(见表 2)。
分组 n 胱抑素C/(mg/L) 尿酸/(μmol/L) PD组 60 1.13±0.41 263.10±47.54 对照组 30 0.91±0.13 296.30±33.81 t — 2.49 3.41 P — < 0.05 < 0.01 表 1 PD组与对照组胱抑素C、尿酸水平比较(x±s)
分组 n 胱抑素C/(mg/L) 尿酸/(μmol/L) PD伴认知功能障碍组 34 1.28±0.42 248.62±43.82 PD不伴认知功能障碍组 26 1.01±0.36 274.18±47.90 t — 2.68 2.12 P — < 0.01 < 0.05 表 2 PD各亚组间胱抑素C、尿酸水平比较(x±s)
-
血清胱抑素C水平与MMSE评分呈明显负相关关系(r=-0.403,P < 0.01);血清尿酸水平与MMSE评分呈正相关关系(r=0.286,P < 0.05)。
血清胱抑素C、尿酸水平与帕金森病伴认知功能障碍的相关性分析
Correlation analysis of the serum levels of cystatin C and uric acid with cognitive impairment in Parkinson's disease
-
摘要:
目的探讨帕金森病(PD)病人血清半胱氨酸蛋白酶抑制剂C(胱抑素C)、尿酸水平的变化,并分析血清胱抑素C、尿酸水平与PD伴认知功能障碍的相关性。 方法选择60例PD病人为PD组,年龄及性别相匹配的30名健康体检者为对照组。对PD组病人行简易智力状况检查量表(MMSE)评分,根据MMSE评分将PD组分为PD伴认知功能障碍组、PD不伴认知功能障碍组。检测各组血清胱抑素C及尿酸水平。 结果PD组血清胱抑素C水平高于对照组(P < 0.05),血尿酸水平明显低于对照组(P < 0.01)。PD伴认知功能障碍组血清胱抑素C水平明显高于不伴认知功能障碍组(P < 0.01),血尿酸水平低于不伴认知功能障碍组(P < 0.05)。血清胱抑素C水平与MMSE评分呈负明显相关关系(r=-0.403,P < 0.01);血清尿酸水平与MMSE评分呈正相关关系(r=0.286,P < 0.05)。 结论血清胱抑素C及尿酸水平与PD伴认知功能障碍有关,可作为PD伴认知功能障碍的早期生物学评估指标。 -
关键词:
- 帕金森病 /
- 认知功能障碍 /
- 半胱氨酸蛋白酶抑制剂C /
- 尿酸
Abstract:ObjectiveTo investigate the changes of serum levels of cystatin C and uric acid in patients with Parkinson's disease(PD), and analyze the correlation of serum levels of cystatin C and uric acid with cognitive impairment. MethodsSixty patients with PD and 30 cases healthy examiners matched for gender and age were divided into the observation group(PD group) and control group, respectively.The PD group were subdivided into the PD complicated with cognitive impairment group and PD complicated without cognitive impairment group according to the mini-mental State Examination(MMSE) score.The serum levels of cystatin C and uric acid in all groups were measured. ResultsThe serum levels of cystatin C and uric acid in PD group were higher and lower than those in control group, respectively(P < 0.05 and P < 0.01).The serum levels of cystatin C and uric acid in PD complicated with cognitive impairment group were higher and lower than those in PD complicated without cognitive impairment group, respectively(P < 0.01 and P < 0.05).The serum level of cystatin C was negatively correlated with MMSE score(P < 0.01), and the serum level of uric acid was positively correlated with MMSE score(P < 0.05). ConclusionsThe serum levels of cystatin C and uric acid are correlated with PD complicated with cognitive impairment, which can be used as an early biological evaluation index in PD complicated with cognitive impairment. -
Key words:
- Parkinson's disease /
- cognitive impairment /
- cystatin C /
- uric acid
-
表 1 PD组与对照组胱抑素C、尿酸水平比较(x±s)
分组 n 胱抑素C/(mg/L) 尿酸/(μmol/L) PD组 60 1.13±0.41 263.10±47.54 对照组 30 0.91±0.13 296.30±33.81 t — 2.49 3.41 P — < 0.05 < 0.01 表 2 PD各亚组间胱抑素C、尿酸水平比较(x±s)
分组 n 胱抑素C/(mg/L) 尿酸/(μmol/L) PD伴认知功能障碍组 34 1.28±0.42 248.62±43.82 PD不伴认知功能障碍组 26 1.01±0.36 274.18±47.90 t — 2.68 2.12 P — < 0.01 < 0.05 -
[1] 刘疏影, 陈彪.帕金森病流行现状[J].中国现代神经疾病杂志, 2016, 16(2):98. doi: 10.3969/j.issn.1672-6731.2016.02.007 [2] WANG YQ, TANG BS, YAN XX, et al.A neurophysiological profile in Parkinson's disease with mild cognitive impairment and dementia in China[J].J Clin Neurosci, 2015, 22(6):981. doi: 10.1016/j.jocn.2014.11.030 [3] 刘婷婷, 宋立友, 李宏岩, 等.帕金森病伴认知功能障碍与血尿酸、同型半胱氨酸相关性的研究进展[J].国际老年医学杂志, 2014, 35(6):276. doi: 10.3969/j.issn.1674-7593.2014.06.011 [4] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病诊断标准(2016版)[J].中华神经科杂志, 2016, 49(4):268. doi: 10.3760/cma.j.issn.1006-7876.2016.04.002 [5] LIEPELT-SCARFONE I, BRANDLE B, YILMAZ R, et al.Progression of prodromal motor and non-motor symptoms in the premotor phase study-2-year follow-up data[J].Eur J Neurol, 2017, 24(11):1369. doi: 10.1111/ene.13397 [6] RAY CK, POEWE W, BROOKS D.Motor and nomotor complications of levodopa:phenomenology, risk factors, and imaging features[J].Mov Disord, 2018, 33(6):909. doi: 10.1002/mds.27386 [7] CHEN W, XU ZM, WANG G, et al.Non-motor symptoms of Parkinson's disease in China:a review of the literature[J].Parkinsonism Relat Disord, 2012, 18(5):446. doi: 10.1016/j.parkreldis.2012.02.002 [8] SHADRINA MI, SLOMINSKY PA, LIMBORSKA SA.Molecular mechanisms of pathogenesis of Parkinson's disease[J].Int Rev Cell Mol Biol, 2010, 281(10):229. [9] BOSE A, BEAL MF.Mitochondrial dysfunction and oxidative stress in induce pluripotent stem cell models of Parkinson's disease[J].Eur Neurosci, 2019, 49(4):525. doi: 10.1111/ejn.14264 [10] HOOK G, YU J, TONEFF T, et al.Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the eysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic[J].J Alzheimers Dis, 2014, 41(1):129. doi: 10.3233/JAD-131370 [11] DORSZEWSKA J, PRENDECKI M, LIANERI M, et al.Molecular effects of ldopa therapy in Parkinson's disease[J].Curr Genomics, 2014, 15(1):11. doi: 10.2174/1389202914666131210213042 [12] DUTTA G, BARBER DS, ZHANG P, et al.Involvement of dopaminergic neuronal cystatin C in neuronal injury-induced microglial activation and neurotoxicity[J].J Neurochem, 2012, 122(4):752. doi: 10.1111/j.1471-4159.2012.07826.x [13] 徐金敏, 陈静, 许冉, 等.合并阻塞性睡眠呼吸暂停综合征的帕金森病患者血清胱抑素C水平的变化[J].中华神经科杂志, 2014, 47(6):365. doi: 10.3760/cma.j.issn.1006-7876.2014.06.003 [14] YANG Q, WANG Y, FENG J, et al.Intermittent hypoxia from obstructive sleep apnea may cause neuronal impairment and dysfunction in central nervous system:the potential roles played by microglia[J].Neuropsychiatr Dis Treat, 2013, 9(8):1077. [15] KITAMURA H, KAMON H, SAWA S, et al.IL-6-STAT3 controls intracellular MHC class Ⅱ alphabeta dimer level through cathepsin S activity in dendritic cells[J].Immunity, 2015, 23(5):491. [16] 叶明, 陈育华, 刘晓林, 等.帕金森病患者血清半胱氨酸蛋白酶抑制剂C水平的变化及其临床意义[J].中华全科医学, 2016, 14(12):2004. [17] LEVY E, SASTRE M, KUMAR A, et al.Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients[J].J Neuropathol Exp Neurol, 2001, 60(1):94. doi: 10.1093/jnen/60.1.94 [18] 梁若冰, 雷晶, 张小宁.帕金森病患者合并认知功能障碍与血清Aβ1-42、胱抑素C、尿酸水平的关系[J].神经损伤与功能重建, 2016, 11(2):131. [19] JESUS S, PEREZ I, CACERES-REDONDO MT, et al.Low serum uric acidconcentration in Parkinson's disease in southern Spain[J].Eur J Neurol, 2013, 20(1):208. doi: 10.1111/j.1468-1331.2012.03745.x [20] ROZYCK A, JAGODZINSKI PP, KOZUBSKI W, et al.Homocysteine level and mechanisms of injury in Parkinson's diseaseas related to MTHFR, MTR, and MTHFD1 genes polymorphisms and L-Dopa treatment[J].Current genomics, 2013, 14(8):534. [21] 张丽娜, 屈洪党, 陈育华, 等.血清尿酸水平与帕金森病不同运动亚型之间的关系[J].蚌埠医学院学报, 2017, 42(7):852. [22] 俱西驰, 屈秋民, 王伟, 等.血清尿酸水平与帕金森病认知功能障碍的关系[J].南京医科大学学报, 2013, 33(1):59. [23] 黄碧霞, 郭少勇.老年帕金森病患者血清同型半胱氨酸及血尿酸水平与认知功能障碍的相关性分析[J].当代医学, 2019, 25(2):100. doi: 10.3969/j.issn.1009-4393.2019.02.041